Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8866771 | 0.98 | EPHX1 (0.48) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| SCHEMBL3917628 | 0.92 | TAAR1 (0.53) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| Hydrochloric Acid SCHEMBL9510561 | 0.90 | TAAR1 (0.52) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| SCHEMBL5332232 | 0.90 | TAAR1 (0.59) | SLC7A5TAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL272604 | 0.85 | EPHX1 (0.61) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| SCHEMBL3451169 | 0.85 | EPHX1 (0.61) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| SCHEMBL468022 | 0.85 | EPHX1 (0.61) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| Hydrochloric Acid SCHEMBL27276749 | 0.83 | EPHX1 (0.58) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| Hydrochloric Acid SCHEMBL28839661 | 0.83 | EPHX1 (0.58) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 | |
| SCHEMBL9323047 | 0.82 | EPHX1 (0.52) | EPHX1SLC7A5TAAR1SLC6A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008123821-A1 | 4, 5-DIHYDRO-LH-IMIDAZOL-2-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS | ALBIREO AB (SE) | 2008-10-16 | — | — | WO | claimed |
| WO-2007017652-A2 | ARYLAKYLAMINES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| EP-0356035-B1 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1996-03-13 | — | — | EP | claimed |
| WO-1991011995-A1 | ARYLALKYL-AMINES AND -AMIDES HAVING ANTICONVULSANT AND NEUROPROTECTIVE PROPERTIES | FISONS CORPORATION (US) | 1991-08-22 | — | — | WO | claimed |
| EP-0356035-A2 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1990-02-28 | — | — | EP | claimed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3485882-A1 | COMPOSITIONS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2948135-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| US-5605916-A | Arylalkyl-amines having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1997-02-25 | — | — | US | disclosed |
| US-5539120-A | Arylalkyl-amines having anticonvulsant and neuroprotective properties | AGENCE SPATIALE EUROPEENNE (FR) | 1996-07-23 | — | — | US | disclosed |
| EP-0356035-B1 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1996-03-13 | — | — | EP | disclosed |
| US-5430044-A | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | FISONS CORPORATION (GB) | 1995-07-04 | — | — | US | disclosed |
| EP-0648489-A1 | Arylalkylamides having neuroprotective properties | FISONS CORPORATION (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0648745-A1 | Arylalkylamine having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1995-04-19 | — | — | EP | disclosed |
| US-5331007-A | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | FISONS CORPORATION (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0356035-A2 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | EPHX1 670/4885SLC7A5 1323/4885TAAR1 123/4885 |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | MECP2, GRIN2A, GRIN2C | EPHX1 2678/4885SLC7A5 2469/4885TAAR1 726/4885 |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | GRIN2A, GRIN2C, GRIN2D | EPHX1 1184/4885SLC7A5 1360/4885TAAR1 193/4885 |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2A, GRIN2C, GRIN2D | EPHX1 1184/4885SLC7A5 1360/4885TAAR1 193/4885 |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | MECP2, GRIN2A, GRIN2B | EPHX1 3685/4885SLC7A5 2014/4885TAAR1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.